Skip to main content
SpringerLink
Log in

FDA says benefits of lorcaserin do not outweigh risk of cancer

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Sharretts J, et al. Cancer Risk Associated with Lorcaserin - The FDA's Review of the CAMELLIA-TIMI 61 Trial. New England Journal of Medicine 383: 1000-1002, No. 11, 10 Sep 2020. Available from: URL: http://doi.org/10.1056/NEJMp2003873

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

FDA says benefits of lorcaserin do not outweigh risk of cancer. Reactions Weekly 1823, 2 (2020). https://doi.org/10.1007/s40278-020-83630-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-83630-x

Search

Navigation